Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept Injection in CTD-ILD (Phase III)
CTR20260545Phase 3Active
- Sponsor
- RemeGen
- Start
- May 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in interstitial lung disease (ILD), sponsored by RemeGen. Started May 2026; status: active.
02
Drugs
telitacicept
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on CTR20260545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260545.